Bioxytran annual r&d spending
2020
2021
2022
2023
2024
2025
Bioxytran R&D Spending Growth & History (BIXT)
Bioxytran's r&d spending was $454,000 for fiscal 2025.
View full Bioxytran company overviewBioxytran annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $454,000 | $341,663 | +304.14% |
| 2024 | 2024-12-31 | $112,337 | −$1.0M | −90.22% |
| 2023 | 2023-12-31 | $1.1M | −$128,559 | −10.06% |
| 2022 | 2022-12-31 | $1.3M | −$735,994 | −36.55% |
| 2021 | 2021-12-31 | $2.0M | $1.5M | +269.82% |
| 2020 | 2020-12-31 | $544,519 | — | — |
Bioxytran quarterly r&d spending
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $255,479 | $152,979 | +149.25% |
| Q1 2026 | 2026-03-31 | $225,479 | −$124,021 | −35.49% |
| Q4 2025 | 2025-12-31 | $2,000 | −$32,337 | −94.18% |
| Q3 2025 | 2025-09-30 | $0 | −$51,000 | — |
| Q2 2025 | 2025-06-30 | $102,500 | $102,500 | — |
| Q1 2025 | 2025-03-31 | $349,500 | $322,500 | +1194.44% |
| Q4 2024 | 2024-12-31 | $34,337 | −$510,101 | −93.69% |
| Q3 2024 | 2024-09-30 | $51,000 | −$265,129 | −83.87% |
| Q2 2024 | 2024-06-30 | $0 | −$149,638 | — |
| Q1 2024 | 2024-03-31 | $27,000 | −$112,004 | −80.58% |
| Q4 2023 | 2023-12-31 | $544,438 | $25,808 | +4.98% |
| Q3 2023 | 2023-09-30 | $316,129 | −$159,743 | −33.57% |
| Q2 2023 | 2023-06-30 | $149,638 | $106,497 | +246.86% |
| Q1 2023 | 2023-03-31 | $139,004 | −$101,121 | −42.11% |
| Q4 2022 | 2022-12-31 | $518,630 | −$247,485 | −32.30% |
| Q3 2022 | 2022-09-30 | $475,872 | $293,910 | +161.52% |
| Q2 2022 | 2022-06-30 | $43,141 | −$675,511 | −94.00% |
| Q1 2022 | 2022-03-31 | $240,125 | −$106,908 | −30.81% |
| Q4 2021 | 2021-12-31 | $766,115 | — | — |
| Q3 2021 | 2021-09-30 | $181,962 | — | — |
| Q2 2021 | 2021-06-30 | $718,652 | — | — |
| Q1 2021 | 2021-03-31 | $347,033 | — | — |
Bioxytran r&d spending trends
Over the last five fiscal years, Bioxytran's r&d spending decreased from $544,519 to $454,000, a change of −$90,519. The latest reported quarter, Q2 2026, shows $255,479.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bioxytran source filings ↗